Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.61 |
| ▸ | STAT3 | P40763 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.56 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959687 | 0.93 | CRBN (0.63) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL22959653 | 0.92 | STAT3 (0.62) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL22959682 | 0.91 | STAT3 (0.61) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL22959805 | 0.91 | STAT3 (0.61) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL21997001 | 0.91 | CRBN (0.67) | CRBNDDB1STAT3CA2TNF | |
| SCHEMBL29880821 | 0.90 | CRBN (0.71) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL23905164 | 0.90 | CRBN (0.59) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL23568549 | 0.89 | CRBN (0.65) | CRBNDDB1STAT3CA2TNF | |
| SCHEMBL23904588 | 0.88 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 | |
| SCHEMBL21997784 | 0.88 | CRBN (0.66) | CRBNDDB1STAT3CA2DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885STAT3 4250/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | CRBN 1616/4885DDB1 798/4885STAT3 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.